A Breast Milk Study in Lactating Women Who Have Been Prescribed Therapeutic Doses of MOTEGRITY® or RESOTRAN® (Prucalopride) for Chronic Idiopathic Constipation to Evaluate Prucalopride Concentrations in Breast Milk, and to Collect Incidental Safety Data From the Nursing Infants
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Prucalopride (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- Sponsors Takeda
- 16 Jun 2023 Planned End Date changed from 30 May 2025 to 31 Dec 2026.
- 16 Jun 2023 Planned primary completion date changed from 30 May 2025 to 31 Dec 2026.
- 01 Feb 2022 Planned initiation date changed from 31 Dec 2021 to 30 Jun 2022.